This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Holman, D. H.
Right arrow Articles by Dong, J. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Holman, D. H.
Right arrow Articles by Dong, J. Y.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, February 2007, p. 182-189, Vol. 14, No. 2
1071-412X/07/$08.00+0     doi:10.1128/CVI.00330-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Two Complex, Adenovirus-Based Vaccines That Together Induce Immune Responses to All Four Dengue Virus Serotypes{triangledown}

David H. Holman,1 Danher Wang,1 Kanakatte Raviprakash,3,4 Nicholas U. Raja,1 Min Luo,1 Jianghui Zhang,1 Kevin R. Porter,3,4 and John Y. Dong1,2*

Division of Biodefense Vaccines, GenPhar Inc., 871 Lowcountry Blvd., Mount Pleasant, South Carolina 29464,1 Department of Microbiology and Immunology, Medical University of South Carolina, 173 Ashley Avenue, Charleston, South Carolina 29403,2 Naval Medical Research Center, 503 Robert Grant Ave., Building 503, Room 3A14A, Silver Spring, Maryland 20910-7500,3 Department of Medicine, Uniformed Services University of Health Sciences, Bethesda, Maryland 208924

Received 11 September 2006/ Returned for modification 11 October 2006/ Accepted 8 December 2006

Dengue virus infections can cause hemorrhagic fever, shock, encephalitis, and even death. Worldwide, approximately 2.5 billion people live in dengue-infested regions with about 100 million new cases each year, although many of these infections are believed to be silent. There are four antigenically distinct serotypes of dengue virus; thus, immunity from one serotype will not cross-protect from infection with the other three. The difficulties that hamper vaccine development include requirements of the natural conformation of the envelope glycoprotein to induce neutralizing immune responses and the necessity of presenting antigens of all four serotypes. Currently, the only way to meet these requirements is to use a mixture of four serotypes of live attenuated dengue viruses, but safety remains a major problem. In this study, we have developed the basis for a tetravalent dengue vaccine using a novel complex adenovirus platform that is capable of expressing multiple antigens de novo. This dengue vaccine is constructed as a pair of vectors that each expresses the premembrane and envelope genes of two different dengue virus serotypes. Upon vaccination, the vaccine expressed high levels of the dengue virus antigens in cells to mimic a natural infection and induced both humoral and cellular immune responses against multiple serotypes of dengue virus in an animal model. Further analyses show the humoral responses were indeed neutralizing against all four serotypes. Our studies demonstrate the concept of mimicking infections to induce immune responses by synthesizing dengue virus membrane antigens de novo and the feasibility of developing an effective tetravalent dengue vaccine by vector-mediated expression of glycoproteins of the four serotypes.

* Corresponding author. Mailing address: Division of Biodefense Vaccines, GenPhar Inc., 871 Lowcountry Blvd., Mount Pleasant, SC 29464. Phone: (843) 884-0120. Fax: (843) 884-0601. E-mail: dongj{at}genphar.com.

{triangledown} Published ahead of print on 27 December 2006.

Clinical and Vaccine Immunology, February 2007, p. 182-189, Vol. 14, No. 2
1071-412X/07/$08.00+0     doi:10.1128/CVI.00330-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Holman, D. H., Penn-Nicholson, A., Wang, D., Woraratanadharm, J., Harr, M.-K., Luo, M., Maher, E. M., Holbrook, M. R., Dong, J. Y. (2009). A Complex Adenovirus-Vectored Vaccine against Rift Valley Fever Virus Protects Mice against Lethal Infection in the Presence of Preexisting Vector Immunity. CVI 16: 1624-1632 [Abstract] [Full Text]  
  • Raviprakash, K., Wang, D., Ewing, D., Holman, D. H., Block, K., Woraratanadharm, J., Chen, L., Hayes, C., Dong, J. Y., Porter, K. (2008). A Tetravalent Dengue Vaccine Based on a Complex Adenovirus Vector Provides Significant Protection in Rhesus Monkeys against All Four Serotypes of Dengue Virus. J. Virol. 82: 6927-6934 [Abstract] [Full Text]  
  • Swenson, D. L., Wang, D., Luo, M., Warfield, K. L., Woraratanadharm, J., Holman, D. H., Dong, J. Y., Pratt, W. D. (2008). Vaccine To Confer to Nonhuman Primates Complete Protection against Multistrain Ebola and Marburg Virus Infections. CVI 15: 460-467 [Abstract] [Full Text]  
  • White, L. J., Parsons, M. M., Whitmore, A. C., Williams, B. M., de Silva, A., Johnston, R. E. (2007). An Immunogenic and Protective Alphavirus Replicon Particle-Based Dengue Vaccine Overcomes Maternal Antibody Interference in Weanling Mice. J. Virol. 81: 10329-10339 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»